Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer,...
-
SAN DIEGO, May 17, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer,...
-
FDA Type B Meeting Feedback Supports Discussion of Topline BICR Results for Repotrectinib in TKI-Naïve ROS1+ NSCLC Patients After 6 Months or Greater Follow-up; FDA Meeting Anticipated in 1Q 2022 ...
-
SAN DIEGO, April 26, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of...
-
Investigational New Drug Application Cleared Study Initiated in Australia, with U.S. Site Activations Now Planned SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc....
-
SAN DIEGO, April 09, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of...
-
Preliminary Clinical Activity Shown, With Tumor Regression in 4 of 5 TKI-Naïve Patients Including 2 Confirmed Partial ResponsesPreliminary Clinical Activity Shown, With Tumor Regression in 3 of 9...
-
Barbara Bodem Joins Board, Appointed Chair of Audit Committee Garry Nicholson Appointed as Interim Board Chair SAN DIEGO, March 31, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc....
-
SAN DIEGO, March 10, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of...
-
SAN DIEGO, March 04, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of...